UNSPSC 51162718: Guaiacol nicotinate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C13H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NL78157RR. Most nations, for tariff and trade purposes, schedule guaiacol nicotinate under HS 29095000 and SITC 51617. As of Q4 2014, GUAIACOL NICOTINATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCCCC1OC(=O)C2CCCNC2.

UNSPSC 51162718 Guaiacol nicotinate is a Commodity code whose recent state and local activity centers on pharmaceutical procurement, though the posted opportunities show limited direct connection to the code's nominal chemical scope. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB (IFB60459723LAS, response due July 26, 2023), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, response due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities, including Oregon. The naloxone procurement targets annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the MMCAP RFP seeks manufacturers to supply comprehensive generic pharmaceutical products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with products required to be available in the marketplace by May 15, 2026. Both opportunities require vendor compliance with cGMP standards, drug supply chain security protocols, E-Verify employment verification, and substantial insurance coverage; MMCAP specifically weights price competitiveness at 75 percent of evaluation scoring. Issuing bodies include county health departments and multistate cooperative purchasing alliances; the MMCAP vehicle serves state departments and local government facilities across multiple participating states.

Recent activity spans Florida and the Upper Midwest (Minnesota and Oregon). The code shows sparse recent state and local posting volume — only two opportunities identified across the recent record. The Seminole County naloxone IFB represents direct community health procurement for opioid response, while the MMCAP RFP reflects broader statewide and multistate pharmaceutical sourcing for distributed government facilities. Neither opportunity is explicitly tagged as carrying set-aside designations for disadvantaged enterprises, though MMCAP reserves discretion over award structure (sole, dual, or multi-award) based on therapeutic considerations and member needs. The gap between the code's chemical nomenclature and the actual pharmaceutical procurement activity suggests either miscategorization in the source data or that guaiacol nicotinate is a minor ingredient or reference code within broader pharmaceutical bidding frameworks.